The present disclosure provides linker compounds of Formula (I) or (II):

##STR00001##

pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. The present disclosure also relates to uses of the linker compounds, scaffolds, and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.

Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.

Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.

The disclosure provides compounds of formula (I),

##STR00001##

wherein R1, R2, R5, R6, R7, L1, L2, W1, W2, and Z1 are as defined herein, and compositions comprising same, and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen.

Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.

Disclosed are new compounds of formulae: ##STR00001##
Wherein: R.sup.1 and R.sup.2 can be independently H; a C.sub.1 to C.sub.6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R.sup.1,R.sup.2 together with the carbon C-6 can be a cyclopentylidene or cyclohexylidene; each of these groups being substituted or not; and R.sup.3 can be a C.sub.1 to C.sub.6 alkyl including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl; or aryl including phenyl, methylphenyl, ethylphenyl, each of these groups being substituted or not. The invention also relates to their method of manufacture and their use for the synthesis of Ara-N.sub.3, Kdo-N.sub.3 and 4eKdo-N.sub.3.

Disclosed are new compounds of formulae: ##STR00001##
Wherein: R.sup.1 and R.sup.2 can be independently H; a C.sub.1 to C.sub.6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R.sup.1,R.sup.2 together with the carbon C-6 can be a cyclopentylidene or cyclohexylidene; each of these groups being substituted or not; and R.sup.3 can be a C.sub.1 to C.sub.6 alkyl including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl; or aryl including phenyl, methylphenyl, ethylphenyl, each of these groups being substituted or not. The invention also relates to their method of manufacture and their use for the synthesis of Ara-N.sub.3, Kdo-N.sub.3 and 4eKdo-N.sub.3.

Processes for the preparation of phosphorylated heptose compounds are provided. Embodiments of the invention relate to the chemical synthesis of heptopyranose phosphate compounds. Also, embodiments of the invention relate to the use of compounds according to the invention in modulating an immune response in a subject.

Processes for the preparation of phosphorylated heptose compounds are provided. Embodiments of the invention relate to the chemical synthesis of heptopyranose phosphate compounds. Also, embodiments of the invention relate to the use of compounds according to the invention in modulating an immune response in a subject.

The invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni (C. jejuni) in a subject comprising one or more monosaccharides comprising one or more MeOPN moieties. Specifically, the invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni (C. jejuni) in a subject comprising one or more MeOPN.fwdarw.6 Gal monosaccharides. The invention also relates to compositions comprising the immunogenic synthetic constructs and methods of inducing an immune response against C. jejuni in a subject comprising administering the immunogenic synthetic constructs, and/or compositions comprising the immunogenic synthetic construct, to the subject.